Matrix metalloproteinase-9 contributes to the increase of tau protein in serum during acute ischemic stroke

J Clin Neurosci. 2010 Aug;17(8):997-9. doi: 10.1016/j.jocn.2010.01.005.

Abstract

Previous studies indicate that tau protein, a marker of damage to neurons, is present in the serum of healthy patients at a concentration approximately 40 percent that of patients with ischemic stroke We assumed that increased serum activity of gelatinases (matrix metalloproteinase [MMP]-2 and MMP-9) can influence the level of tau protein in serum, probably due to disruption of the blood-brain barrier. We obtained blood sera from 31 patients admitted within the first 24 hours of ischemic stroke on days 1, 5 and 10, following the onset of stroke. Tau protein was detected in the serum of 12 patients (38.7 percent). The highest MMP-9 activity was recorded on day 5 (p < 0.05). Serum gelatinase activity did not differ between tau protein-positive or -negative individuals. However, a high degree of correlation between mean MMP-9 activity and the maximum tau protein level was observed for patients with detectable tau protein (r = 0.71, p = 0.009). Our study suggests that MMP-9 can increase the tau protein level in the sera of patients during acute ischemic stroke.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Brain Ischemia / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Matrix Metalloproteinase 2 / blood
  • Matrix Metalloproteinase 9 / blood*
  • Middle Aged
  • Patient Selection
  • Stroke / blood*
  • Time Factors
  • tau Proteins / blood*

Substances

  • tau Proteins
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9